每年專案
個人檔案
學歷
- 2000 臺灣大學醫學院藥研所博士
- 1996 臺灣大學醫學院藥研所碩士
- 1994 臺北醫學院藥學系學士
經歷
- 2021.11- 臺北醫學大學新藥開發研究中心主任
- 2018.01- 臺北醫學大學藥學院院長
- 2017.06- 臺北醫學大學生技醫藥商品化中心主任
- 2015.08-2022.07 臺北醫學大學藥學院生技製藥研究中心主任
- 2013.09-2017.12 臺北醫學大學藥學院副院長
- 2013.08- 臺北醫學大學中草藥臨床藥物研發博士學位學程
- 2013.08- 臺北醫學大學癌症生物學與藥物研發博士學位學程
- 2012.10-2016.12 臺北醫學大學藥物有機合成核心服務實驗室主任
- 2012.08- 臺北醫學大學藥物科學學科教授
- 2012.02-2012.07 臺北醫學大學藥物科學學科副教授
- 2008.02-2012.01 臺北醫學大學藥學系副教授
- 2004.10-2008.01 臺北醫學大學藥學系助理教授
獎項
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
研究興趣
- 抗癌小分子化合物設計與合成
- 有機合成
指紋
查看啟用 Jing-Ping Liou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
網路
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
-
脂肪酸代謝所調控的神經炎症在構建造成腫瘤復發之神經元-巨噬細胞-膠質瘤迴路中的角色－可穿透血腦障蔽腦障蔽且抑制惡性神經膠母細胞瘤發炎之藥物研發(1/3)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 科技部
-
-
-
-
-
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment
Wu, T. Y., Chen, M., Chen, I. C., Chen, Y. J., Chen, C. Y., Wang, C. H., Cheng, J. J., Nepali, K., Chuang, K. H. & Liou, J. P., 4月 2023, 於: Journal of Advanced Research. 46, p. 159-171研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取2 引文 斯高帕斯（Scopus） -
Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects
Nepali, K., Wu, A. C., Lo, W. L., Chopra, B., Lai, M. J., Chuang, J. Y. & Liou, J. P., 2月 2023, 於: European Journal of Medicinal Chemistry. 248, 115054.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
2,6-Difluorobenzamide derivatives as store-operated calcium channel (SOC) inhibitors
Wang, Y. S., Yeh, T. K., Chang, W. C., Liou, J. P., Liu, Y. M. & Huang, W. C., 12月 5 2022, 於: European Journal of Medicinal Chemistry. 243, 114773.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier
Sharma, R., Chatterjee, E., Mathew, J., Sharma, S., Rao, N. V., Pan, C. H., Lee, S. B., Dhingra, A., Grewal, A. S., Liou, J. P., Guru, S. K. & Nepali, K., 10月 5 2022, 於: European Journal of Medicinal Chemistry. 240, 114602.研究成果: 雜誌貢獻 › 文章 › 同行評審
2 引文 斯高帕斯（Scopus） -
A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model
Yeh, L-Y., Fang, Y-T., Lee, H-S., Liu, C-H., Chen, Y-Y., Lo, Y-C., Laiman, V., Liou, J-P., Chung, K. F., Chuang, H-C. & Lin, C-H., 5月 2022, 於: Frontiers in Medicine. 9, 794025.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取
資料集
-
Additional file 1: of Suberoylanilide hydroxamic acid represses glioma stem-like cells
Chang, K. (Creator), Wang, J. (Creator), Chuang, J. (Creator), Ko, C. (Contributor), Hsu, T. (Contributor), Chang, W. (Creator), Yeh, S. (Contributor), Liou, J. (Creator), Liu, J. (Contributor) & Hsu, C. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3596465_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3596465_d1.v1
資料集: Dataset
-
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Creator), Liou, J. (Creator), Teng, C. (Contributor) & Pan, S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
資料集: Dataset
-
Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Creator), Liou, J. (Creator), Teng, C. (Contributor) & Pan, S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202881.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202881/1
資料集: Dataset
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I. (Contributor), Kuo, C. (Contributor), Liou, J. (Creator) & Chang, J. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
資料集: Dataset
-
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Creator), Liou, J. (Creator), Teng, C. (Contributor) & Pan, S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
資料集: Dataset